Currently, pharmaceutical companies worldwide have embarked on drug research with GDF15 as a novel therapeutic target, encompassing various fields such as obesity, cancer, and anorexia syndrome. The gene discussed is GDF15; the disease is obesity due to melanocortin 4 receptor deficiency.